Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $771.3 million for Q1 2026.

• In Q1 2026, Other Operating Expenses changed N/A year-over-year to $771.3 million; the TTM figure through Mar 2026 stood at $781.3 million (up 2150.66% YoY), while the FY2025 annual figure was $10.0 million, up 118.73% from the prior year.
• Other Operating Expenses was $771.3 million for Q1 2026 at Regeneron Pharmaceuticals, up from $10.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $771.3 million in Q1 2026 to a low of -$15.5 million in Q4 2024.
• Historically, Other Operating Expenses has averaged $58.6 million across 5 years, with a median of $550000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses tumbled 3200.0% in 2024, then jumped 225.0% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $6.6 million in 2022, then slumped by 92.42% to $500000.0 in 2023, then sank by 3200.0% to -$15.5 million in 2024, then soared by 164.52% to $10.0 million in 2025, then jumped by 7613.0% to $771.3 million in 2026.
• The last three Other Operating Expenses figures came in at $771.3 million (Q1 2026), $10.0 million (Q3 2025), and -$15.5 million (Q4 2024), per Business Quant data.